Amphenol has reclaimed some ground this week, yet the question hanging over the stock is whether a 7% rally and a fresh analyst initiation are enough to declare the selloff over — or merely a pause in it.
The rebound is real. APH closed at $82.84 on Tuesday, up 6.7% on the week and 2.6% in Tuesday's session alone. That is a meaningful move off the lows. But context matters. The stock is still down 47% over the past month. As last week's note highlighted, APH was at $77.65 when short sellers were accelerating their build — the current price still sits well below the July earnings-driven peak that briefly sent the stock toward $160-plus. The July print itself was striking: the stock jumped 11% the day after results and added nearly 20% over the following five days. Whatever drove that optimism has not been fully recovered.
The short-interest picture has continued to evolve since last week's note, and the direction remains the same. Estimated short interest climbed again this week, now at 2.4% of the free float — up 8% on the week and a remarkable 85% higher than a month ago. In absolute terms, that is still a low rate for a name of Amphenol's size, and the lending market is far from stressed. Borrow availability is extraordinarily loose: roughly 7,830% of short interest, meaning the pool of shares available to lend dwarfs the current short position by a wide margin. Cost to borrow is just 0.36%, barely changed on the week. This is not a crowded short where a squeeze is plausible — it is a moderate and growing bearish bet against a stock that has already fallen sharply. Options positioning is similarly unremarkable. The put/call ratio sits at 1.11, almost exactly in line with its 20-day average, with a z-score near zero. Neither side of the options market is pressing a strong view.
The Street is split in ways that are difficult to reconcile right now. The bullish read is that Bernstein just initiated coverage with an Outperform rating and a $99 target — the freshest analyst action on the stock, filed Wednesday. BNP Paribas also raised its target to $110, reiterating Outperform. Against that, TD Cowen slashed its target from $175 to $90 on September 9 while holding a Hold rating, and Barclays cut from $200 to $100 while keeping Overweight — both moves reflecting the scale of the price dislocation rather than a change in directional view. The consensus sits at Buy with a mean target of $99.39, implying roughly 20% upside from current levels. That is internally consistent with the price, and the numbers hang together — no stale target anomalies here. On valuation, the trailing PE has drifted down to about 26.6x, the EV/EBITDA to 15.9x. Both have recovered slightly with the week's bounce but remain well off levels from a month ago. The bull case rests on AI infrastructure spending and EV-driven connector demand; the bear case points to weakening industrial production and supply-chain drag in automotive. Factor scores lean constructive on dividend quality (100th percentile) and EPS surprise history (71st percentile), but EPS momentum is near the bottom of the range on both 30-day and 90-day horizons.
Institutional flows add one notable data point. Capital Research added over 23 million shares in the period through August 31 — a meaningful addition for a large-cap name. T. Rowe Price added 10.3 million shares. On the other side, Norges Bank trimmed 5.3 million shares. The Vanguard Group's 13G/A filing from March shows a reduction to 0% from 10.25%, though Vanguard Capital Management separately filed a 13G in April showing a 7.47% stake — a structural reorganisation of a large passive position rather than a bearish signal. No 13D activist is on the register. Insider activity from early August was dominated by option exercises and same-day sales by the CFO, General Counsel, and HR chief — compensation-related mechanics, not conviction trades.
The next earnings print is October 28. Given the stock's history of large reactions — up 11% on the day after July results, and a subdued 2.5% after April's — the Q3 report will be the definitive test of whether the post-July collapse reflected a genuine fundamental reset or an overshooting of sentiment. The key question at that print is not whether Amphenol is growing, but whether the AI and data-centre demand narrative can be reaffirmed at a time when the stock has already priced in considerable pessimism.
See the live data behind this article on ORTEX.
Open APH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
